Vol. 7, Issue 2, Part C (2025)

Every year, millions of people's health and quality of life are impacted by the rising number of respiratory disease cases worldwide. Many hospital admissions and fatalities are caused by acute respiratory infections (ARIs) and chronic respiratory disorders (CRDs), which call for advanced therapies that make the delivery of medications with regulated release to particular target sites. Various nanoparticles (NPs), including lipid, liposome, protein, carbon-based, polymeric, metallic, oxide, and magnetic NPs, have been investigated to meet this need. Because of their benefits for targeted effects, sustained drug release, and patient compliance, NPs can be used as drug delivery systems to increase the effectiveness of commercial medications. An updated synopsis of recent developments in the use of NPs as drug delivery systems to treat respiratory tract illnesses, including ARIs and CRDs, is provided in the current study. The most recent uses reported in the literature were taken into account, and the advantages and disadvantages of NPs in the field of medication administration are examined.